Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rituxan RA Approval Raises The Stakes, But With A Lower Price

Executive Summary

Genentech/Biogen Idec are pricing Rituxan (rituximab) for rheumatoid arthritis at a lower cost for most patients than the closest comparable biologic, Bristol-Myers Squibb's Orencia (abatacept)

You may also be interested in...



Genentech’s Forecast: Biotech Pioneer Looking To Small Molecules

Genentech, one of the pioneers of the biotech industry, will be bringing a growing number of small molecules into the clinic as it seeks to diversify its pipeline, according to VP-Clinical Hematology/Oncology David Schenkein

Genentech’s Forecast: Biotech Pioneer Looking To Small Molecules

Genentech, one of the pioneers of the biotech industry, will be bringing a growing number of small molecules into the clinic as it seeks to diversify its pipeline, according to VP-Clinical Hematology/Oncology David Schenkein

Orencia Outperforming Rituxan In RA, Bristol Says; Branded DTC To Start Soon

Physicians more frequently prescribe Bristol-Myers Squibb's Orencia than Genentech/Biogen Idec's Rituxan for rheumatoid arthritis, Bristol Worldwide Pharmaceuticals President Lamberto Andreotti said

Related Content

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel